-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Lumexa Imaging Hldgs, Lowers Price Target to $15

Benzinga·04/14/2026 14:37:13
Listen to the news
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $23 to $15.